Regeneron Pharmaceuticals, Inc.
REGN
$527.78
-$19.89-3.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.30% | 8.79% | 5.16% | 5.24% | 4.84% |
| Total Other Revenue | -10.61% | -3.94% | 21.45% | 44.06% | 38.72% |
| Total Revenue | 7.52% | 8.27% | 5.72% | 6.46% | 5.90% |
| Cost of Revenue | 13.07% | 13.55% | 10.98% | 12.05% | 16.76% |
| Gross Profit | 2.26% | 3.46% | 1.08% | 1.64% | -2.68% |
| SG&A Expenses | 6.59% | 12.28% | 13.54% | 15.69% | 19.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,012.50% | 795.24% | 271.95% | 125.47% | 97.72% |
| Total Operating Expenses | 11.31% | 13.37% | 12.00% | 14.02% | 18.75% |
| Operating Income | -1.09% | -2.43% | -6.65% | -7.66% | -14.99% |
| Income Before Tax | 23.31% | 13.83% | 13.55% | -3.94% | -13.18% |
| Income Tax Expenses | 163.25% | 49.49% | -18.27% | -44.27% | -61.06% |
| Earnings from Continuing Operations | 16.63% | 11.61% | 16.62% | 0.53% | -7.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.63% | 11.61% | 16.62% | 0.53% | -7.77% |
| EBIT | -1.09% | -2.43% | -6.65% | -7.66% | -14.99% |
| EBITDA | 0.37% | -0.88% | -4.81% | -5.83% | -12.55% |
| EPS Basic | 15.65% | 10.35% | 15.72% | 0.31% | -7.49% |
| Normalized Basic EPS | 2.88% | 2.08% | -2.56% | -1.91% | -8.58% |
| EPS Diluted | 16.07% | 10.18% | 15.29% | -0.16% | -8.00% |
| Normalized Diluted EPS | 3.25% | 1.95% | -2.96% | -2.38% | -9.13% |
| Average Basic Shares Outstanding | 0.65% | 1.08% | 0.75% | 0.19% | -0.28% |
| Average Diluted Shares Outstanding | 0.09% | 1.19% | 1.14% | 0.66% | 0.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |